Updates are available Correction dated 2023-07-17
Click to view Correction: https://doi.org/10.1038/s41591-023-02500-7
-
Authors
van Dorp, Jeroen https://orcid.org/0000-0002-1395-612X
Pipinikas, Christodoulos
Suelmann, Britt B. M.
Mehra, Niven
van Dijk, Nick https://orcid.org/0000-0001-5115-5086
Marsico, Giovanni
van Montfoort, Maurits L.
Hackinger, Sophie
Braaf, Linde M.
Amarante, Tauanne
van Steenis, Charlaine
McLay, Kirsten
Daletzakis, Antonios
van den Broek, Daan
van de Kamp, Maaike W.
Hendricksen, Kees
de Feijter, Jeantine M.
Boellaard, Thierry N.
Meijer, Richard P.
van der Heijden, Antoine G.
Rosenfeld, Nitzan
van Rhijn, Bas W. G.
Jones, Greg
van der Heijden, Michiel S. https://orcid.org/0000-0002-4407-7881
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb provided the study drugs and funding for the trial.
- License Information
-
More Information
Article History
Received: 5 July 2022
Accepted: 22 December 2022
First Online: 2 February 2023
Change Date: 17 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-023-02500-7
Competing interests
: M.S.v.d.H. received funding, paid to the Netherlands Cancer Institute, from Bristol Myers Squibb to finance the NABUCCO study. No other authors have received financial support for the work in this manuscript, and no medical writer was involved at any stage of the preparation of this manuscript.
